Research Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs decreased their FY2025 earnings per share estimates for Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($3.18) for the year, down from their previous estimate of ($3.00). The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

A number of other analysts also recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, March 26th. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Leerink Partners cut their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Finally, Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.80.

Remove Ads

Lexeo Therapeutics Trading Down 10.1 %

Shares of LXEO stock traded down $0.42 during trading hours on Thursday, hitting $3.68. 265,086 shares of the company's stock traded hands, compared to its average volume of 502,204. The stock has a market cap of $122.30 million, a PE ratio of -1.17 and a beta of 3.85. The stock's 50 day simple moving average is $4.05 and its 200 day simple moving average is $6.53. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company's stock valued at $577,000 after acquiring an additional 33,013 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock worth $129,000 after purchasing an additional 7,803 shares during the period. Vestal Point Capital LP increased its stake in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company's stock valued at $7,684,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Verition Fund Management LLC increased its stake in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company's stock valued at $7,027,000 after purchasing an additional 355,928 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.